Global Cancer Drug Therapy Market Professional Survey Report 2019

Kidney cancer or renal cancer is one of the ten most frequently diagnosed cancers, found mainly in people aged 60 or above. According to the estimates of the American Cancer Society (ACS), 61,560 new kidney cancer cases and 14,080 deaths would occur in 2015. Due to the increasing prevalence with no cure of this deadly disease, till date, there is an imminent need for effective kidney cancer drugs.

The renal cancer drug therapy market has witnessed a dramatic change in its treatment paradigm over the last three decades. Although, there are a variety of treatment options available, innovators have now shifted their focus towards more targeted therapies and immunotherapies. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors boosting the growth of the market. Strong pipeline and fast-emerging treatments are expected to further boost the market during the analysis period. However, high cost of drugs, looming off-patents and uncertain reimbursement policies are some of the factors that are likely to restrain the market growth.

Winning a physicians confidence regarding the cost, efficacy and dosage would lead to a higher acceptance of drugs in the market. Additionally, immunotherapies would emerge as an opportunity for innovators in the kidney cancer drugs market. Furthermore, untapped geographies with a high undiagnosed patient base would offer lucrative opportunities for the innovators in future. However, overcoming the generic drugs competition would be a key challenge for the leading innovators.

The global Cancer Drug Therapy market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Cancer Drug Therapy volume and value at global level, regional level and company level. From a global perspective, this report represents overall Cancer Drug Therapy market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Cancer Drug Therapy in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Cancer Drug Therapy manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Amgen / Allergan
Argos Therapeutics
AstraZeneca
Aveo Pharmaceuticals
Bayer
Exelixis
Incyte
Merck
Roche
Bristol-Myers Squibb
Eisai
Exelixis
Genentech (Roche)
Novartis
Pfizer
Prometheus Labs

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Targeted Therapy
Chemotherapy
Immunotherapy

Segment by Application
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)